Precigen (NASDAQ:PGEN) Price Target Raised to $10.00 at Stifel Nicolaus

Precigen (NASDAQ:PGENFree Report) had its price objective hoisted by Stifel Nicolaus from $7.00 to $10.00 in a report released on Monday morning, Benzinga reports. Stifel Nicolaus currently has a buy rating on the biotechnology company’s stock.

Several other analysts have also commented on the stock. JMP Securities reissued a market outperform rating and set a $14.00 target price on shares of Precigen in a research note on Wednesday, March 20th. StockNews.com raised shares of Precigen to a sell rating in a research note on Tuesday, May 21st. Cantor Fitzgerald reissued an overweight rating on shares of Precigen in a research note on Wednesday, May 15th. JPMorgan Chase & Co. downgraded shares of Precigen from a neutral rating to an underweight rating in a research report on Friday, March 22nd. Finally, HC Wainwright restated a buy rating and issued a $6.00 price target on shares of Precigen in a research report on Monday. Two analysts have rated the stock with a sell rating and four have given a buy rating to the stock. According to data from MarketBeat.com, the company has a consensus rating of Hold and a consensus price target of $10.00.

View Our Latest Stock Analysis on PGEN

Precigen Price Performance

Precigen stock opened at $1.56 on Monday. The firm has a 50 day simple moving average of $1.39 and a 200-day simple moving average of $1.36. The stock has a market capitalization of $393.78 million, a PE ratio of -4.00 and a beta of 1.88. Precigen has a 12-month low of $0.84 and a 12-month high of $1.88.

Precigen (NASDAQ:PGENGet Free Report) last released its earnings results on Tuesday, May 14th. The biotechnology company reported ($0.10) EPS for the quarter, missing the consensus estimate of ($0.09) by ($0.01). Precigen had a negative net margin of 1,781.72% and a negative return on equity of 65.36%. The business had revenue of $1.07 million for the quarter, compared to analyst estimates of $1.54 million. During the same period in the prior year, the company earned ($0.10) earnings per share. On average, analysts forecast that Precigen will post -0.36 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Precigen

Several hedge funds have recently made changes to their positions in the company. Patient Capital Management LLC lifted its position in Precigen by 16.2% in the 4th quarter. Patient Capital Management LLC now owns 15,983,700 shares of the biotechnology company’s stock worth $21,418,000 after buying an additional 2,230,524 shares in the last quarter. Vanguard Group Inc. lifted its position in Precigen by 0.3% in the 1st quarter. Vanguard Group Inc. now owns 6,768,234 shares of the biotechnology company’s stock worth $9,814,000 after buying an additional 19,875 shares in the last quarter. Iridian Asset Management LLC CT lifted its position in Precigen by 4.3% in the 1st quarter. Iridian Asset Management LLC CT now owns 2,091,274 shares of the biotechnology company’s stock worth $3,032,000 after buying an additional 86,340 shares in the last quarter. Opaleye Management Inc. lifted its position in Precigen by 9.0% in the 4th quarter. Opaleye Management Inc. now owns 1,012,500 shares of the biotechnology company’s stock worth $1,357,000 after buying an additional 84,000 shares in the last quarter. Finally, Sanders Morris Harris LLC purchased a new stake in Precigen in the 1st quarter worth approximately $1,022,000. Hedge funds and other institutional investors own 33.51% of the company’s stock.

Precigen Company Profile

(Get Free Report)

Precigen, Inc operates as a discovery and clinical-stage biopharmaceutical company that develops gene and cell therapies using precision technology to target diseases in therapeutic areas of immuno-oncology, autoimmune disorders, and infectious diseases. It operates through two segments, Biopharmaceuticals and Exemplar.

Further Reading

Analyst Recommendations for Precigen (NASDAQ:PGEN)

Receive News & Ratings for Precigen Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Precigen and related companies with MarketBeat.com's FREE daily email newsletter.